Ivan Kriulin

Dr. Ivan Kriulin

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
EAEkaterina Alexeeva
Ekaterina Alexeeva
RTRustem F. Tepaev
Rustem F. Tepaev
ISIlia Y. Shilkrot
Ilia Y. Shilkrot
TDTatyana M. Dvoryakovskaya
Tatyana M. Dvoryakovskaya
ASAleksander G. Surkov
Aleksander G. Surkov
ДМДворяковская Татьяна Маратовна
Дворяковская Татьяна Маратовна
In most cases, COVID-19 has a favorable outcome. However, the risk of developing critical forms of the disease, including secondary hemophagocytic lymphohistiocytosis HLH (cytokine storm syndrome), remains high. This dictates the interest in studying pathogenetic mechanisms, features of the clinical picture, laboratory and instrumental criteria for covid-19 disease. The article analyzes the causes of acute respiratory distress syndrome and multiple organ failure as manifestations of HLH. The necessity of monitoring signs of hyperinflammation (ferritin, C-reactive protein, etc., biomarkers of inflammation) and activation of thrombosis is substantiated, in order to make timely decisions about the beginning of pathogenetic therapy. However, there are limitations for routine testing of the level of Pro-inflammatory cytokines. Information about the diagnostic criteria of HLH is summarized, and the expediency of these criteria for establishing secondary HLH, which has complicated the course of COVID-19, is emphasized.

12 February 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
EAEkaterina Alexeeva
Ekaterina Alexeeva
TDTatyana Dvoryakovskaya
Tatyana Dvoryakovskaya
AFAnna Fetisova
Anna Fetisova
IKIvan Kriulin
Ivan Kriulin
EKElizaveta Krekhova
Elizaveta Krekhova
Mikhail KostikMikhail Kostik
Mikhail Kostik
Background: Immunosuppressive therapy (methotrexate and biological agents) for juvenile idiopathic arthritis (JIA) is associated with an increased risk of severe infections, higher infection rates, treatment interruptions, failure to achieve disease remission, and recurrent disease flares. Our study aimed to evaluate the safety and efficacy of simultaneous immunization with 13-valent polysaccharide conjugate vaccines (PCV13) against S. pneumoniae (SP) and Hemophilus influanzae type b infections (HibV) in children with JIA without systemic manifestations. Methods: A total of 371 non-systemic JIA patients who received 13PCV and HibV were included in this prospective cohort study. In every patient, we evaluated clinical, laboratory, anti-SP, and anti-Hib IgG antibodies before vaccination, three weeks after, and six months after, and all adverse events (AEs) were collected during the study. The number and duration of acute respiratory infection (ARI) episodes and requirements for antibacterial treatment and AE six months before and after the baseline were collected. Results: The levels of the Ig G anti-SP and anti-Hib antibodies increased in the 3 weeks after vaccination; then, anti-SP antibodies slightly decreased and anti-Hib antibodies remained increased during the whole study, as well as in a part of the patients with a protective titer. During the study, there were no patients with significant flares, and the main JIA outcomes gradually decreased during the trial. The number of patients with uveitis remained equal, as well as the part of the patients with active, low-active, and inactive uveitis. There was no significant rise in the hs-CRP or S100 protein after the vaccination. Previous or ongoing treatment with non-biological (p = 0.072) and biological (p = 0.019) disease-modified anti-rheumatic drugs affected the Hib and did not affect the anti-SP protective titer at the end of the study. Within 6 months following vaccination, the number of ARI episodes (p < 0.001) and the number of courses of antibacterial treatment (p < 0.0001) decreased twice. The median duration of ARI episodes decreased four times (p < 0.0001). Mild AEs (injection site reactions and short-term fever episodes) were found in 58 (15.6%) patients with JIA, and 1 patient (0.2%) developed an SAE. Conclusions: Simultaneous vaccination against pneumococcal and Hib infections reduces the frequency and duration of episodes of ARI, as well as the number of courses of antibacterial drugs, and does not lead to significant JIA flares. The number of reported AEs is consistent with what was expected.

24 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
EAEkaterina Alexeeva
Ekaterina Alexeeva
ITIrina T. Tsulukiya
Irina T. Tsulukiya
TDTatyana M. Dvoryakovskaya
Tatyana M. Dvoryakovskaya
DKDmitry Kudlay
Dmitry Kudlay
IKIvan Kriulin
Ivan Kriulin
Mikhail KostikMikhail Kostik
Mikhail Kostik
Background: Some patients with juvenile idiopathic arthritis (JIA) can successfully undergo withdrawal of treatment with anti-tumor necrosis factor alpha (anti-TNF-α) therapy, which may reduce economic and treatment-related burdens and the potential morbidity of treatment for at least 6 months. Currently, no guidelines exist on the appropriate withdrawal of anti-TNF-α therapy once clinically inactive disease (CID) has been achieved. This study aimed to assess the possibility of withdrawing anti-TNF-α therapy in children with non-systemic JIA after achieving long-term clinical remission. Methods: This single-center retrospective cohort study included data from 137 non-systemic JIA patients treated with anti-TNF-α therapy (etanercept or adalimumab) and having maintained CID for at least 24 months during treatment. Demographic, laboratory, and treatment data were collected at JIA onset, at the initiation of anti-TNF-α therapy, every 6 months during therapy, and at the time of disease flare. Anti-TNF-α therapy was discontinued abruptly after discussing it with the patients and their families in each case. Outcomes were assessed using standard criteria for remission in JIA (ACRpedi and Wallace criteria). Results: Following withdrawal of TNF-α inhibitors, 93/137 patients (67.9%) experienced a disease flare, with a median time to flare of 7 months (3; 14). Thirty-two percent of patients remained in remission for a median of 63 months. Absence of flare during the first 22 months after discontinuation was associated with prolonged biologic-free remission (odds ratio 682; 95% CI 38.6–12,062; p < 0.0001), with 83% sensitivity and 100% specificity (area under the ROC curve 0.967). Most flares involved arthritis (76%) and/or uveitis (24%), primarily affecting knees, ankles, and wrists. Inflammatory markers were generally lower at flare compared to baseline. Biological therapy was resumed in 84/93 patients (90.3%), achieving at least a 50% improvement according to ACRpedi criteria within 3 months and remission according to Wallace criteria within 6 months. Conclusion: Over two-thirds of patients with non-systemic JIA who achieve CID experience a flare within seven months of anti-TNF-α discontinuation. Re-initiation of biologic therapy is effective in restoring remission. These results indicate that prolonged biologic-free remission is possible in a subset of patients, highlighting the need for individualized withdrawal strategies and careful post-discontinuation monitoring.

17 June 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
DFD.S. Fomina
D.S. Fomina
MLM.S. Lebedkina
M.S. Lebedkina
UMU.A. Markina
U.A. Markina
IKIvan Kriulin
Ivan Kriulin
SKS.O. Kotenko
S.O. Kotenko
EAEkaterina Alexeeva
Ekaterina Alexeeva
The COVID-19 vaccination has become a way of effective prevention of the decease for most people globally. However, there is a cohort of patients who are not able to form a full-fledged immune response due to primary or secondary immunodeficiency conditions caused by genetic disorders, severe course of chronic diseases, due to their age or the use of drugs that suppress the immune response. The use of monoclonal viral antibodies for immunocompromised patients is the most efficient method of pre- and post-contact and even long-term prevention, as well as the treatment of coronavirus infection. Monoclonal antibodies are obtained from B-lymphocytes of patients recovered from COVID-19. As a result of further modification aimed at increasing of the efficiency and reducing the risk of unwanted phenomena in the use, the virus-neutralizing recombinant monoclonal antibodies of the IgG1 class were designed to implement preventive and therapeutic schemes for COVID-19. Treatment of a new coronavirus infection with drugs with direct etiotropic action is most effective when prescribing in the early stages of the disease, which is especially relevant in patients at risk for a severe/critical clinical course of the disease and can be performed as outpatient clinical procedures. The article analyzes the results of clinical studies of efficacy and safety of mono- and combined drugs of monoclonal antibodies to SARS-CoV-2 in patients with the new coronavirus infection, as well as potential possibilities for their use for the treatment of COVID-19 caused by the new SARS-CoV-2 strains with multiple mutations on the example of the Omicron strain.

1 January 2023 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
ITI.T. Tsulukiya
I.T. Tsulukiya
EAEkaterina Alexeeva
Ekaterina Alexeeva
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
AFA.N. Fetisova
A.N. Fetisova
AAA.V. Anikin
A.V. Anikin
MSM.Sh. Shingarova
M.Sh. Shingarova

1 January 2022 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
IKIvan Kriulin
Ivan Kriulin
EAEkaterina Alexeeva
Ekaterina Alexeeva
ISI.Yu. Shilkrot
I.Yu. Shilkrot
TDT.M. Dvoryakovskaya
T.M. Dvoryakovskaya
Secondary hemophagocytic syndrome (SHS) is a life-threatening complication of systemic juvenile idiopathic arthritis (SJIA, syn.: systemic-onset juvenile idiopathic arthritis). Timely treatment of SHS can improve outcomes and reduce mortality rates. There has been little evidence worldwide on the effectiveness of therapy for SHS in patients with SJIA, including the use of genetically engineered biopharmaceutical drugs (GEBDs). Objective. To evaluate the efficacy of different treatment regimens for SHS in patients with SJIA. Patients and methods. This study included 100 patients with SJIA complicated by SHS who were examined and treated at the rheumatology department of the National Medical Research Center for Children’s Health (Moscow) from August 2010 to May 2021. All patients met the criteria for SJIA and SHS diagnosis. The efficacy of different therapy regimens for SHS was assessed according to treatment response criteria and achievement of the clinically inactive status of SHS. The Kaplan-Meier survival analysis was used to investigate the proportion and duration of the period prior to SHS recurrence (relapse-free interval) after the end of therapy, including the use of GEBDs for the treatment of SJIA. The proportion of relapse-free survival cases and the duration of relapse-free interval were assessed within 36 months in 79 of 100 patients (89/114 (78%) SHS cases). Results. Medical records of 100 patients with 114 cases of SHS were retrospectively studied. In 84/114 (73%) cases, SHS developed in patients not receiving GEBDs (“biologically naïve”), and in 30/114 (26%) cases, SHS developed against the background of GEBD therapy (“biologically non-naïve”). Combination therapy, which included intravenous (dexamethasone 17.9 [10; 20] mg/m2/day or methylprednisolone 12.1 [5; 20] mg/kg/day) and oral (prednisolone 0.9 [0.5; 2] mg/kg/day) glucocorticosteroids (GCs), as well as cyclosporine (CsA) at a dose of 4.5 [2; 7] mg/kg/day and normal human immunoglobulin (syn. intravenous immunoglobulin; IVIG) at a dose of 1.5 [0.3; 2] g/kg. In 24/114 (21%) cases, GEBDs were prescribed for the treatment of SHS: in 11 (10%) – tocilizumab, in 8 (7%) – canakinumab, and in 5 (4%) – rituximab. Hemophagocytic syndrome resolved in 111/114 (97%) cases, lethal outcome was registered in 3/114 (3%) cases. Conclusion. Response to treatment and inactive SHS status achievement in the shortest possible time were recorded when using a treatment regimen that included intravenous and oral administration of GCs, as well as CsA and IVIG, regardless of the background use of GEBDs for the treatment of SJIA. In “biologically naïve” patients, response to treatment developed faster, and the proportion and duration of relapse-free interval were significantly greater than in “biologically non-naïve” patients. Key words: secondary hemophagocytic syndrome, systemic juvenile idiopathic arthritis, treatment, genetically engineered biopharmaceutical drugs